PreludeDx to Present Data for a Novel Molecular Biosignature to Predict Radiation Therapy Benefit in Early-Stage Invasive Breast Cancer at the 2023 San Antonio Breast Cancer Symposium
29 nov. 2023 07h00 HE
|
PreludeDx
PreludeDx to Present Data for a Novel Molecular Biosignature to Predict Radiation Therapy Benefit in Early-Stage Invasive Breast Cancer at the 2023 SABCS
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
28 nov. 2023 17h05 HE
|
Arvinas Inc.
-- Six abstracts have been accepted for presentation, including updated data on vepdegestrant alone and in combination with palbociclib (IBRANCE®) -- NEW HAVEN, Conn. and NEW YORK, Nov. 28,...
Data Demonstrating Precede Biosciences' Ability to Determine HER2 Status from 1mL of Plasma to be Presented at the 2023 San Antonio Breast Cancer Symposium
28 nov. 2023 17h02 HE
|
Precede Biosciences, Inc.
BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class liquid biopsy platform, announces that data...
Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer Symposium
28 nov. 2023 09h01 HE
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
Monoclonal Antibodies Market Size Worth USD 572.62 Billion in 2032 | Emergen Research
28 nov. 2023 08h17 HE
|
Emergen Research
Vancouver, Nov. 28, 2023 (GLOBE NEWSWIRE) -- The global monoclonal antibodies market size was USD 204.42 billion in 2022 and is expected to register a revenue CAGR of 10.8% during the forecast...
Arvinas Announces Oversubscribed $350 Million Private Placement
27 nov. 2023 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference
22 nov. 2023 08h05 HE
|
Celcuity Inc.
MINNEAPOLIS, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its...
Organic Remedies Donates $20,000 to Support Pennsylvania Breast Cancer Survivors and Their Families
22 nov. 2023 07h36 HE
|
Organic Remedies
Organic Remedies, a medical marijuana organization, raised $20,000 to support the Pennsylvania Breast Cancer Coalition, PBCC.
PreludeDx™ to Present Multiple Presentations at the 2023 San Antonio Breast Cancer Symposium
16 nov. 2023 07h30 HE
|
PreludeDx
PreludeDx today announced that data will be presented in two separate poster presentations at the 2023 San Antonio Breast Cancer Symposium (SABCS).
AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update
15 nov. 2023 07h30 HE
|
AIM ImmunoTech Inc.
– Highlights continued execution across Ampligen® clinical development programs – Company is well positioned to achieve multiple value-driving milestones during remainder of 2023 and 2024 – Will...